A Case of Rapid Enlargement and Ruptured Abdominal Aortic Aneurysm (rAAA) in a Patient Treated with Chemotherapy Using Bevacizumab (BV)

Bibliographic Information

Other Title
  • ベバシズマブ治療中急速拡大・破裂した腹部大動脈瘤の1例
  • 症例 ベバシズマブ治療中急速拡大・破裂した腹部大動脈瘤の1例
  • ショウレイ ベバシズマブ チリョウ チュウ キュウソク カクダイ ・ ハレツ シタ フクブ ダイ ドウミャクリュウ ノ 1レイ

Search this article

Description

We report a case of enlarged and ruptured abdominal aortic aneurysm (rAAA) in a patient who was treated with chemotherapy using bevacizumab (BV). A 70-year-old man presented to our hospital with severe abdominal pain for the duration of chemotherapy (using BV for recurrence of rectal carcinoma). The pulsatile mass was palpable in the abdomen. He was alert and his blood pressure was 199/116 mmHg. Enhanced computed tomography (CT) revealed fusiform abdominal aortic aneurysm with a diameter of 48 mm and post-peritoneal hematoma. The diameter of the aneurysm was 43 mm, 6 month previously. We diagnosed rAAA, and considering the adverse effect of BV, selected endovascular aneurysm repair (EVAR) for treatment. Emergency aortography was performed, and no extravasation was found. We selected the Gore Excluder endoprosthesis and completed the operation with no endoleak. Enhanced CT revealed no endoleak 2 days after EVAR and the patient was discharged on postoperative day 4. The patient was in good condition, and chemotherapy was resumed one month after EVAR. It was possible that administration of BV was associated with the rupture. Therefore, in this case, we selected the precise method of treatment considering the adverse effect of BV.

Journal

References(5)*help

See more

Details 詳細情報について

Report a problem

Back to top